Cytomegalovirus (CMV): Epidemiology Forecast to 2027
Summary The report "Cytomegalovirus (CMV): Epidemiology Forecast to 2027", report provides an overview of the risk factors, comorbidities, and global and historical trends for Cytomegalovirus (CMV) disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).
Cytomegalovirus (CMV) is a common virus belonging to the Herpesviridae family.CMV is present in up to 60% of adults in high-income countries and up to 100% of adults in low- and middle-income countries.
In individuals with healthy immune systems, Cytomegalovirus (CMV) infections are typically asymptomatic, and the virus establishes a lifelong latent infection.Certain populations, such as people living with human immunodeficiency virus (HIV), solid organ transplant (SOT) patients, allogeneic hematopoietic stem cell transplant (allo-HSCT) patients, and infants infected in utero, are vulnerable to symptomatic disease caused by primary CMV infections or reactivation.
CMV disease may also occur in critically ill immunocompetent patients (Siciliano et al., 2014). Depending on the population, CMV disease can present as end-organ disease (infection and symptoms in lung, gastrointestinal (GI) tract, liver, retina, or other organs), CMV syndrome (fever, fatigue, leukopenia, and/or thrombocytosis), or congenital CMV (cCMV) (symptoms ranging from mild manifestations to premature birth and neurologic sequelae.
In 2017, there were 9,691 diagnosed incident cases of Cytomegalovirus (CMV) disease in the 7MM.The US had the most cases (5,885), while Japan had the fewest (271).
Epidemiologists forecast that the number of CMV cases in the 7MM will increase to 10,704 in 2027, at an Annual Growth Rate (AGR) of 1.05%. All countries besides Germany are expected to see an increase in CMV cases. HIV patients made up the greatest burden of CMV cases in the 7MM in 2017 (3,734 cases), followed closely by SOT patients (3,696 cases).cCMV accounted for the fewest cases (979).
The report includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0-10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM.
Scope - The Cytomegalovirus (CMV) Epidemiology Forecast Report provides an overview of the risk factors and global trends of CMV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). - This report provides an overview of the risk factors, comorbidities, and global and historical trends for CMV disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0-10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM. - The CMV epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists. - The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy The CMV Epidemiology Forecast report will allow you to - - Develop business strategies by understanding the trends shaping and driving the global CMV market. - Quantify patient populations in the global CMV market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CMV therapeutics in each of the markets covered. - Understand magnitude of CMV population by population at risk.
Our reports have been used by over 10K customers, including:
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
Healthy future: Despite the mounting likelihood of new regulation, industry revenue will likely grow Abstract Cryogenic Biobanking Services Since the landmark scientific achievement of human genome sequencing in 2003, the Cryogenic Biobanking Services industry is increasingly viewed as the link between...
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029
Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
Anatomic pathology track and trace solutions market projected to grow at a CAGR of 10.4% The anatomic pathology track and trace solutions market is projected to reach USD 695.7 million by 2023 from USD 424.2 million in 2018, at a CAGR of 10.4% from 2018 to 2023. The increasing volume of diagnostic tests performed in anatomic...
With a population of more than 1 billion, China is the worldâ€™s largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro...
Opportunity Analyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche’s Esbriet and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval...
Commercial Real Estate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.